Thoracentesis

Quick Answer

Thoracentesis (pleural tap) is a bedside procedure for sampling (diagnostic) or draining (therapeutic) pleural fluid. Ultrasound guidance is mandatory (BTS 2010) - reduces pneumothorax from 10-15% to 1-2% (PMID: 20696656). Patient positioned sitting, leaning forward (preferred) or lateral decubitus. Insert needle ABOVE the rib (superior border) to avoid the intercostal neurovascular bundle. Use Z-track technique (pull skin 2cm caudally before insertion). Maximum 1.5L drainage per session to prevent re-expansion pulmonary edema (REPE). Light's Criteria distinguish exudate (Protein >30 g/L OR Protein ratio >0.5 OR LDH ratio >0.6) from transudate. Parapneumonic effusion requires drainage if: pH under 7.2, glucose under 3.4 mmol/L (60 mg/dL), LDH >1000 IU/L, or frank pus (empyema). Complications: pneumothorax (1-2% with USS), hemothorax (rare), REPE (under 1%), infection (under 0.5%).

---

CICM Exam Focus

SAQ Exam Stems

• "Describe the technique for diagnostic thoracentesis, including patient positioning, site selection, ultrasound guidance, and Z-track method" (10 marks)
• "A patient with pneumonia develops a pleural effusion. The pleural fluid shows: pH 7.15, glucose 2.1 mmol/L, LDH 1850 IU/L. Interpret these results and outline management" (8 marks)
• "Using Light's Criteria, classify an effusion with: pleural protein 42 g/L, serum protein 65 g/L, pleural LDH 320 IU/L, serum LDH 180 IU/L. Calculate the ratios and provide the differential diagnosis" (6 marks)
• "A patient develops cough and dyspnea after draining 2L of pleural fluid. What is the likely diagnosis, pathophysiology, and management?" (6 marks)
• "List the indications for intercostal chest drain insertion vs therapeutic thoracentesis in parapneumonic effusion" (4 marks)

Hot Case Presentations

• ICU patient with large pleural effusion causing hypoxia - performing USS-guided thoracentesis, interpreting results
• Post-thoracentesis respiratory distress - recognizing REPE vs pneumothorax
• Complex parapneumonic effusion - grading, drainage decisions, fibrinolytic therapy (MIST-2)
• Malignant effusion in end-of-life patient - symptom control, communication with family

Viva Topics

• Technique: USS landmarks (diaphragm, lung, fluid), positioning, Z-track, insertion above rib, volume limits
• Light's Criteria: Calculation, interpretation, "pseudo-exudate" in diuretic therapy (serum-effusion albumin gradient)
• Parapneumonic grading: Simple vs complicated vs empyema, pH/glucose/LDH thresholds, drainage decisions
• Complications: Pneumothorax (mechanism, USS vs blind rates), REPE (pathophysiology, risk factors, prevention), hemothorax (intercostal artery injury)
• Evidence base: BTS 2010/2023 guidelines, MIST-2 trial (tPA/DNase), Feller-Kopman REPE study

---

Key Points

Critical Alert: ULTRASOUND IS MANDATORY: BTS 2010 guidelines state that pleural procedures should NOT be performed without ultrasound guidance. Pneumothorax rate: 10-15% blind vs 1-2% with USS (PMID: 20696656).

Critical Alert: pH under 7.2 = DRAIN: Parapneumonic effusion with pH under 7.2, glucose under 3.4 mmol/L, or LDH >1000 IU/L requires chest drain - antibiotics alone are insufficient.

1. Ultrasound guidance is mandatory - reduces pneumothorax by 70%, increases success rate (PMID: 20696656)
2. Patient positioning: Sitting upright, leaning forward with arms resting on table (optimal); or lateral decubitus with affected side down
3. Insert needle ABOVE the rib - neurovascular bundle runs along inferior border of rib above
4. Z-track technique - pull skin 2cm caudally before insertion to create oblique tract, prevents persistent leak
5. Maximum 1.5L per session - prevents re-expansion pulmonary edema (REPE); stop immediately if cough/dyspnea develop
6. Light's Criteria: Exudate if ANY ONE of: Protein >30 g/L, Protein ratio >0.5, LDH ratio >0.6, LDH >2/3 upper limit normal
7. Empyema criteria: pH under 7.2, glucose under 3.4 mmol/L (60 mg/dL), LDH >1000 IU/L, frank pus, positive Gram stain/culture
8. Parapneumonic effusion management: Simple (antibiotics), Complicated (chest drain), Empyema (drain + consider surgery)
9. MIST-2 trial: tPA 10mg + DNase 5mg twice daily improves drainage in complicated effusions (PMID: 21830966)
10. Complications: Pneumothorax 1-2% (USS), hemothorax under 0.5%, REPE under 1%, vasovagal 1-2%

---

Definition and Epidemiology

Definition

Thoracentesis (pleural tap, pleural aspiration) is the percutaneous insertion of a needle or catheter into the pleural space to:

• Diagnostic: Sample pleural fluid for analysis (50-100 mL)
• Therapeutic: Drain symptomatic pleural effusion (up to 1.5L per session)

Epidemiology

Aetiology Distribution

Most Common Causes (Western Countries):

• Congestive heart failure: 35-40% (transudate)
• Pneumonia/parapneumonic: 20-25% (exudate)
• Malignancy: 15-20% (exudate)
• Pulmonary embolism: 5-10% (exudate or transudate)
• Cirrhosis (hepatic hydrothorax): 5% (transudate)
• Tuberculosis: under 5% developed countries, >20% endemic areas (exudate)

Australian/NZ Context:

• Similar distribution to Western countries
• Higher TB rates in Aboriginal and Torres Strait Islander populations (10-15x general population)
• Mesothelioma higher due to historical asbestos exposure (mining, construction)
• Remote communities: delayed presentation, limited diagnostic capability

---

Indications

Diagnostic Thoracentesis

Note: All new pleural effusions should have diagnostic thoracentesis unless the cause is clinically obvious (e.g., known heart failure responding to diuretics) - PMID: 20696656.

1. New-onset unilateral pleural effusion (all patients)
2. Bilateral effusions with atypical features (fever, asymmetry, chest pain)
3. Suspected parapneumonic effusion/empyema (pneumonia with persistent fever)
4. Suspected malignant effusion (cancer diagnosis, unexplained weight loss)
5. Suspected tuberculous effusion (risk factors, lymphocytic predominance)
6. Unexplained effusion (no obvious cause)
7. Clinical deterioration in patient with known effusion
8. Suspected hemothorax (trauma, post-procedural)
9. Chylothorax evaluation (milky fluid, elevated triglycerides)

Therapeutic Thoracentesis

1. Symptomatic relief (dyspnea, orthopnea from large effusion)
2. Respiratory compromise (hypoxia, tachypnea)
3. Bridge to definitive management (pre-pleurodesis, pre-surgery)
4. Recurrent malignant effusion (palliation when not candidate for IPC/pleurodesis)
5. Hepatic hydrothorax (symptomatic, refractory to diuretics)

ICU-Specific Indications

• Mechanically ventilated patient with large effusion - may improve ventilation/oxygenation
• Suspected ventilator-associated pneumonia with effusion - exclude empyema
• Unexplained sepsis with pleural effusion - exclude pleural infection
• Difficult weaning with large effusion - therapeutic drainage may facilitate extubation

---

Contraindications

Absolute Contraindications

Relative Contraindications

Clinical Pearl: Coagulopathy is NOT an absolute contraindication: Studies show bleeding complications are rare even with INR >1.5 or platelets 25-50,000 when USS-guided technique is used. Routine correction is NOT recommended (PMID: 20696656).

NOT Contraindications (Common Misconceptions)

• Anticoagulation (therapeutic heparin/warfarin) - proceed with USS guidance
• Single functioning kidney - not relevant to chest procedure
• Previous thoracentesis at same site
• Ipsilateral pneumonectomy (no lung to puncture!)

---

Applied Anatomy and Physiology

Pleural Anatomy

Pleural Space:

• Potential space between visceral (lung surface) and parietal (chest wall) pleura
• Normal volume: 5-15 mL of pleural fluid
• Fluid distribution: gravity-dependent (posterior costophrenic angles when supine, lateral when lateral decubitus)

Pleural Fluid Physiology:

• Production: Parietal pleura (systemic circulation, higher hydrostatic pressure)
• Absorption: Parietal pleural lymphatics (primarily) and visceral pleura
• Turnover: 0.1-0.2 mL/kg/hour (up to 1 L/day can be absorbed)
• Starling forces govern fluid movement across pleural membranes

Effusion Formation Mechanisms:

1. Transudative: Altered Starling forces (increased hydrostatic pressure, decreased oncotic pressure)
   • Heart failure, cirrhosis, nephrotic syndrome, hypoalbuminemia
2. Exudative: Increased permeability, impaired lymphatic drainage
   • Infection, malignancy, inflammation, pulmonary embolism

Chest Wall Anatomy

Layers (Superficial to Deep):

1. Skin
2. Subcutaneous tissue
3. Serratus anterior (lateral), latissimus dorsi (posterior)
4. External intercostal muscle
5. Internal intercostal muscle
6. Innermost intercostal muscle
7. Endothoracic fascia
8. Parietal pleura
9. Pleural space

Intercostal Neurovascular Bundle:

Critical Alert: NERVE-ARTERY-VEIN (from above downward) runs along the INFERIOR border of each rib, in the costal groove. Insert needle at the SUPERIOR border of the lower rib.

• Location: Costal groove on inferior border of rib
• Order (superior to inferior): Vein → Artery → Nerve
• Clinical importance: Puncture causes hemothorax, neuropathic pain
• Avoidance: Insert needle immediately ABOVE the rib (superior border of lower rib)
• Collateral vessels: Posterior intercostal artery gives branches at mid-axillary line - vessel position less predictable here
• Elderly patients: Tortuous vessels may not follow typical course - USS Doppler helpful

Diaphragm Position

• Right hemidiaphragm: Higher than left (liver underneath)
• At end-expiration: Approximately rib 10-11 posteriorly, rib 6 anteriorly
• Elevated in: Obesity, ascites, abdominal distension, phrenic nerve palsy
• USS essential: Dynamic visualization prevents subdiaphragmatic puncture (liver/spleen)

Optimal Puncture Sites

Primary Site (Preferred):

• Posterior axillary line or midscapular line
• 7th-9th intercostal space (varies with diaphragm position)
• Patient sitting upright, leaning forward

Alternative Site:

• Mid-axillary line, 5th-7th intercostal space
• Used for lateral decubitus position

Avoid:

• Below 9th intercostal space (diaphragm/abdominal organs)
• Anterior chest (heart, internal mammary vessels)
• Near spine (posterior intercostal artery main trunk)

---

Ultrasound Guidance

Critical Alert: BTS 2010 Guidelines (PMID: 20696656): "Thoracic ultrasound guidance for pleural procedures should be performed whenever possible. It should be available 24 hours a day."

Evidence for Ultrasound

Ultrasound Technique

Equipment:

• Curvilinear (abdominal) probe: 2-5 MHz (deeper structures)
• Linear (vascular) probe: 5-10 MHz (superficial detail, intercostal vessels)

Scanning Approach:

1. Patient position: Sitting upright, leaning forward, arms resting on table
2. Probe placement: Start at posterior axillary line, 7th-8th intercostal space
3. Orientation: Indicator toward patient's head (longitudinal) or anterior (transverse)

Structures to Identify:

• shimmering at pleural interface, A-lines | | Pleural fluid | Anechoic (black) collection, may have internal echoes | | Diaphragm | Hyperechoic curved line, moves with respiration | | Liver/Spleen | Solid organ texture below diaphragm |

Fluid Assessment:

Measurements:

• Depth to pleural fluid: Measure skin to fluid distance
• Fluid depth: Maximum pocket depth (>10mm generally required for safe tap)
• Distance to diaphragm: Ensure adequate margin of safety

Real-Time vs Mark-and-Tap

• Real-time USS guidance: Needle visualized entering fluid - PREFERRED
• Mark-and-tap: Site marked with USS, procedure done without real-time guidance
• BTS recommendation: If mark-and-tap used, procedure must be performed immediately (patient should not move between marking and procedure)

---

Technique: Diagnostic Thoracentesis

Pre-Procedure

Patient Preparation:

1. Explain procedure, risks, benefits, alternatives
2. Obtain informed consent (written or documented verbal)
3. Review coagulation (INR, platelets) - correct only if active bleeding or severe coagulopathy
4. Withhold anticoagulation if possible (not mandatory)
5. Establish IV access
6. Have oxygen available
7. Ensure monitoring (SpO2, HR, BP)

Positioning:

Clinical Pearl: Optimal position: Sitting upright at edge of bed, leaning forward over bedside table with arms resting on pillow. This maximizes posterior costophrenic angle depth and separates ribs.

• Sitting upright, leaning forward: Preferred - maximizes fluid at posterior costophrenic angle
• Lateral decubitus (affected side down): For patients unable to sit - fluid layers dependently
• Supine with head elevated: Suboptimal but acceptable in ventilated patients

Equipment:

• Ultrasound machine with curvilinear probe
• Sterile gloves, gown, drapes
• Chlorhexidine 2% (preferred) or povidone-iodine
• Local anesthetic: Lidocaine 1-2% (10-20 mL)
• 21G or 22G needle (diagnostic), 18G or catheter-over-needle (therapeutic)
• 50mL syringe (diagnostic), larger syringes or drainage bag (therapeutic)
• Three-way tap
• Sterile specimen containers: biochemistry, cytology, microbiology, pH (blood gas syringe)

Procedure Steps

Step 1: Ultrasound Assessment

1. Identify pleural effusion, measure depth
2. Identify diaphragm, ensure adequate distance from puncture site
3. Identify safe entry point (>10mm fluid depth)
4. Check for loculations, septations
5. Mark site with indelible pen (if not real-time guidance)

Step 2: Sterile Preparation

1. Don sterile gown and gloves
2. Clean skin with chlorhexidine 2%, allow to dry 2 minutes
3. Apply sterile drapes to create wide sterile field
4. Prepare equipment on sterile trolley

Step 3: Local Anesthesia

1. Raise skin wheal with 25G needle
2. Advance needle perpendicular to chest wall, anesthetizing track
3. Anesthetize periosteum of rib (very sensitive)
4. Anesthetize parietal pleura - patients often feel sharp pain when pleura reached
5. Aspirate during advancement to confirm not in vessel and to confirm pleural entry
6. Use 10-20 mL lidocaine 1% liberally along entire track

Step 4: Z-Track Technique

Note: Z-Track: Pull the skin 2cm caudally (inferiorly) with your non-dominant hand before needle insertion. This creates an oblique track through tissues that seals when skin is released after needle withdrawal.

1. Use non-dominant hand to retract skin 2cm caudally
2. Maintain traction throughout procedure
3. Purpose: Prevents persistent pleural fluid leak, reduces pneumothorax risk

Step 5: Needle Insertion

1. Insert needle at superior border of lower rib (avoids neurovascular bundle)
2. Advance perpendicular to chest wall with constant aspiration
3. Entry to pleural space: Sudden loss of resistance, fluid aspirates freely
4. For diagnostic tap: 50-100 mL sufficient
5. For therapeutic tap: Connect to drainage system

Step 6: Sample Collection

1. Biochemistry: Protein, LDH, glucose, pH (blood gas syringe, on ice)
2. Microbiology: Gram stain, culture (aerobic/anaerobic), TB culture if indicated
3. Cytology: Ideally 50-100 mL for adequate cell yield
4. Additional: Lipids (chylothorax), amylase (esophageal rupture, pancreatitis), hematocrit (hemothorax)

Step 7: Completion

1. Withdraw needle while releasing Z-track traction
2. Apply pressure and sterile dressing
3. Dispose of sharps safely
4. Document procedure, volume drained, complications

Post-Procedure

• Monitor SpO2 for 30-60 minutes
• Post-procedure CXR: NOT routinely required if USS-guided, no symptoms (BTS 2010)
• Indications for CXR: Aspiration of air during procedure, new symptoms (dyspnea, chest pain), clinical concern for pneumothorax

---

Technique: Therapeutic Thoracentesis

Volume Limits

Critical Alert: Maximum 1.5L per session - higher volumes increase risk of re-expansion pulmonary edema (REPE). Stop IMMEDIATELY if patient develops cough, chest tightness, or dyspnea (PMID: 17400840).

Technique Differences from Diagnostic

1. Larger bore needle/catheter: 16-18G or catheter-over-needle device
2. Drainage system: Three-way tap and 50mL syringe, or vacuum bottle, or gravity drainage bag
3. Slower drainage: Allow gradual lung re-expansion
4. Symptom monitoring: Stop if cough, chest tightness, dyspnea develop
5. Volume documentation: Record total volume drained

Pleural Manometry

• Indication: Large-volume thoracentesis (>1.5L), suspected trapped lung
• Technique: Water manometer connected to drainage system
• Normal pleural pressure: -5 to -10 cmH2O at rest
• Stop drainage if: Pleural pressure falls below -20 cmH2O (elastance >14.5 cmH2O/L)
• Trapped lung: Minimal pressure change despite volume drainage (lung cannot expand)

---

Pleural Fluid Analysis

Light's Criteria

Note: Light's Criteria (PMID: 4261818): Developed in 1972, remains gold standard for distinguishing exudative from transudative effusions with 98% sensitivity for exudates.

Exudate if ANY ONE of the following:

Sensitivity/Specificity:

• Sensitivity for exudate: 98%
• Specificity for exudate: 83%
• Problem: 25-30% of transudates are misclassified as exudates (especially diuretic therapy)

Serum-Effusion Albumin Gradient

Clinical Pearl: "Pseudo-exudate": If Light's criteria suggest exudate but clinical picture suggests transudate (e.g., heart failure on diuretics), calculate Serum-Effusion Albumin Gradient.

Gradient >12 g/L = likely transudate despite meeting Light's criteria.

• Calculation: Serum albumin - Pleural fluid albumin
• Transudate: Gradient >12 g/L
• Useful when: Diuretic therapy concentrates pleural fluid protein, creating "pseudo-exudate"

Additional Pleural Fluid Tests

Parapneumonic Effusion Classification

Critical Alert: Complicated parapneumonic effusion and empyema require chest tube drainage - antibiotics alone are insufficient. The presence of ANY of pH under 7.2, glucose under 3.4 mmol/L, LDH >1000 IU/L, positive Gram stain, or frank pus mandates drainage.

Classification Table:

pH Measurement

Note: pH measurement technique: Collect pleural fluid in heparinized blood gas syringe, transport on ice, analyze within 1 hour on blood gas analyzer. Do NOT use pH paper or bedside meters - inaccurate.

• Threshold for drainage: pH under 7.2 (BTS guideline PMID: 20696656)
• Collection: Heparinized syringe (as for ABG)
• Transport: On ice to blood gas machine
• Analysis: Blood gas analyzer (NOT pH strips/paper)
• False low pH: Delay in processing, lidocaine contamination

---

Specific Effusion Types

Malignant Pleural Effusion (MPE)

Characteristics:

• Exudative (99%)
• Often bloody (hemorrhagic in 30-50%)
• Lymphocyte predominant
• Glucose may be low (poor prognosis if under 3.4 mmol/L)
• pH may be low (poor prognosis if under 7.3)
• Cytology positive in 60% (first tap), 75% (second tap), 85% (third tap)

Common Causes:

1. Lung cancer (35%)
2. Breast cancer (25%)
3. Lymphoma (10%)
4. Mesothelioma (5-10%)
5. Other: ovarian, gastric, unknown primary

Management:

• Diagnostic thoracentesis with cytology
• Repeat cytology if first negative (improves yield)
• Therapeutic thoracentesis for symptom relief
• Definitive options: Indwelling pleural catheter (IPC), talc pleurodesis, VATS

Tuberculous Pleural Effusion

Characteristics:

• Exudative
• Lymphocyte predominant (>80% lymphocytes)
• Low glucose (often under 3.4 mmol/L)
• Low pH (often under 7.3)
• Elevated ADA (>40 U/L - sensitivity 92%, specificity 89%)
• AFB smear positive in under 10%, culture positive in 20-40%
• Pleural biopsy culture positive in 50-80%

Australian Context:

• Higher incidence in Aboriginal and Torres Strait Islander populations
• Common in migrants from endemic regions
• High index of suspicion required
• Notify public health if confirmed

Hemothorax

Definition: Pleural fluid hematocrit >50% of peripheral blood hematocrit

Causes:

• Trauma (penetrating, blunt)
• Iatrogenic (post-thoracentesis, CVC insertion, cardiac surgery)
• Malignancy
• Pulmonary embolism with infarction
• Coagulopathy
• Aortic dissection/rupture

Management:

• Large-bore chest tube (28-32 Fr)
• Blood transfusion if significant hemorrhage
• Surgical exploration if: >1500 mL initial drainage, >200 mL/hr for 2-4 hours

Hepatic Hydrothorax

Definition: Pleural effusion in cirrhotic patient without cardiopulmonary disease

Mechanism: Direct passage of ascites through diaphragmatic defects

Characteristics:

• Transudative (usually)
• Right-sided (85%), bilateral (15%), left-sided (rare)
• May occur without clinically evident ascites

Management:

• Sodium restriction, diuretics (as for ascites)
• Therapeutic thoracentesis for symptom relief
• TIPS for refractory cases
• Liver transplantation definitive

Chylothorax

Definition: Lymphatic fluid (chyle) in pleural space

Diagnosis: Triglycerides >1.2 mmol/L (110 mg/dL), or presence of chylomicrons

Causes:

• Trauma/Surgery (thoracic duct injury) - 50%
• Malignancy (lymphoma) - 30%
• Other: LAM, sarcoidosis, TB, congenital

Management:

• NPO or medium-chain triglyceride diet
• Octreotide (reduces lymphatic flow)
• Drainage (chest tube or IPC)
• Thoracic duct ligation/embolization if persistent

---

Complications

Pneumothorax

Incidence:

• Ultrasound-guided: 1-2% (PMID: 20145575)
• Blind technique: 10-15%

Mechanism:

• Lung puncture
• Air entry through needle/catheter during procedure
• Post-procedure air leak through tract

Risk Factors:

• No ultrasound guidance
• Small effusion (under 10mm)
• Loculated effusion
• Mechanical ventilation
• Uncooperative patient
• Inexperienced operator

Prevention:

• Mandatory ultrasound guidance
• Z-track technique
• Avoid aspiration during needle advancement
• Patient positioning to maximize fluid pocket

Management:

• Small (under 2cm rim): Observation, repeat CXR in 24 hours
• Symptomatic or large: Chest tube insertion
• Tension pneumothorax: Immediate decompression

Re-Expansion Pulmonary Edema (REPE)

Critical Alert: REPE is a rare but potentially fatal complication occurring after rapid drainage of large pleural effusions. Stop drainage IMMEDIATELY if patient develops persistent cough, chest tightness, or dyspnea.

Incidence: under 1% overall, higher with large-volume drainage

Pathophysiology:

1. Chronic lung collapse leads to surfactant depletion, capillary damage
2. Rapid re-expansion causes reperfusion injury
3. Increased vascular permeability, inflammatory response
4. Unilateral (usually) or bilateral pulmonary edema

Risk Factors (PMID: 17400840):

• Drainage >1.5L in single session
• Chronic lung collapse (>7 days)
• Young age (20-40 years)
• Large pneumothorax drainage
• Rapid drainage (vs slow gravity drainage)
• Use of negative pressure suction

Clinical Features:

• Onset: During or within 24 hours of procedure
• Persistent cough during drainage (STOP immediately)
• Progressive dyspnea, chest tightness
• Hypoxia, tachypnea
• Frothy sputum
• CXR: Unilateral (ipsilateral) pulmonary edema

Prevention:

• Limit drainage to 1.5L per session
• Slow drainage (gravity, not suction)
• Stop immediately if symptoms develop
• Consider pleural manometry (stop if pressure less than -20 cmH2O)

Management:

• Supportive care (oxygen, NIV if needed)
• Diuretics (limited evidence)
• Mechanical ventilation if severe hypoxia
• Usually resolves in 24-72 hours

Hemothorax/Bleeding

Incidence: under 1% with ultrasound guidance

Causes:

• Intercostal artery laceration (most common)
• Intercostal vein injury
• Chest wall hematoma
• Lung laceration

Risk Factors:

• No ultrasound (vessels not visualized)
• Insertion at inferior rib border
• Coagulopathy, anticoagulation
• Multiple passes

Prevention:

• Ultrasound with Doppler to identify vessels
• Insert at superior border of rib
• Single-pass technique
• Correct severe coagulopathy if possible

Management:

• Small hematoma: Observation, analgesia
• Significant hemothorax: Chest tube, blood transfusion
• Ongoing bleeding: Interventional radiology (embolization), surgical exploration

Other Complications

---

Evidence Base: Key Trials

BTS Pleural Disease Guidelines 2010 (PMID: 20696656)

Key Recommendations:

• Ultrasound should be available 24/7 for pleural procedures
• All pleural aspirations should be ultrasound-guided
• Complicated parapneumonic effusion (pH under 7.2) requires drainage
• tPA/DNase for loculated effusions not draining (based on MIST-2)
• Maximum 1.5L drainage recommended per session

Light's Criteria (PMID: 4261818)

Original Study (1972):

• 150 patients with pleural effusions
• Established exudate criteria: Protein ratio >0.5, LDH ratio >0.6, LDH >2/3 ULN
• Sensitivity 98%, Specificity 83% for exudates
• Remains gold standard 50+ years later

MIST-2 Trial (PMID: 21830966)

Study Design:

• RCT of 210 patients with pleural infection
• 4 arms: tPA + DNase, tPA alone, DNase alone, placebo

Key Findings:

• tPA + DNase: Significantly improved drainage, reduced surgery, shorter hospital stay
• tPA alone: No benefit
• DNase alone: No benefit (trend toward harm)
• Combination therapy is key

Clinical Implication:

• tPA 10mg + DNase 5mg BD for complicated/loculated parapneumonic effusions
• Intrapleural instillation via chest tube

Feller-Kopman REPE Study (PMID: 17400840)

Study Design:

• Prospective study of 185 large-volume thoracenteses
• Mean drainage 1.67L (some >2L)

Key Findings:

• REPE rate: 0.5% (1 patient)
• Symptom-limited drainage is safe even for large volumes
• Pleural manometry most accurate predictor
• Chest tightness/cough during procedure: Stop immediately

Clinical Implication:

• Traditional 1L limit may be overly conservative
• Symptom-guided drainage appropriate
• Pleural manometry useful for very large effusions

Gordon et al. 2010 - Ultrasound Meta-analysis (PMID: 20145575)

Key Findings:

• Ultrasound reduces pneumothorax from 10-15% (blind) to 2-3% (guided)
• Ultrasound reduces failed taps from 33% to 2%
• Real-time guidance superior to mark-and-tap

---

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Populations

Note: Aboriginal and Torres Strait Islander Australians have higher rates of conditions causing pleural effusions, including tuberculosis (10-15× general population), rheumatic heart disease, and community-acquired pneumonia. Cultural safety considerations are essential when performing invasive procedures.

Epidemiological Considerations:

• Tuberculosis: 10-15× higher incidence than general population (PMID: 29940628)
• Rheumatic heart disease: 10-20× higher, may present with pericardial/pleural effusions
• Pneumonia and empyema: Higher hospitalization rates, often delayed presentation
• Renal disease: Higher rates of nephrotic syndrome, transudative effusions
• Liver disease: Higher rates of alcohol-related cirrhosis, hepatic hydrothorax

Cultural Safety:

1. Communication:

   • Explain procedure in plain language
   • Use interpreter services if English not first language
   • Allow time for patient to ask questions
   • Check understanding ("teach back" method)

2. Family involvement:

   • Extended family often involved in health decisions
   • May require consultation with Elders before consent
   • Allow family members to be present during procedure if patient wishes
   • Family meetings for serious diagnoses (malignancy, TB)

3. Aboriginal Health Workers/Liaison Officers:

   • Involve early, especially for complex procedures
   • Essential for navigating cultural protocols
   • Can facilitate communication and trust
   • Help coordinate follow-up, especially for remote patients

4. Remote and rural considerations:

   • Many patients from remote communities
   • Limited access to ultrasound and expertise in remote settings
   • May require retrieval to regional/tertiary center
   • RFDS may need to perform therapeutic drainage pre-transfer for respiratory compromise
   • Ensure adequate analgesia for long transfers post-procedure

5. Follow-up challenges:

   • Geographic distances, limited transport
   • Need for culturally appropriate follow-up arrangements
   • Telehealth options where available
   • Coordination with remote clinics and Aboriginal Medical Services

Maori Health Considerations (New Zealand)

Epidemiological Considerations:

• Higher rates of respiratory infections, TB, rheumatic heart disease
• Health inequities require proactive approach

Cultural Safety:

1. Whanau (family) involvement: Collective decision-making is important
2. Tikanga (cultural protocols): Respect for cultural practices
3. Te reo Maori: Offer Maori interpreters if preferred
4. Maori Health Workers: Involve for support and cultural guidance
5. Follow-up: Ensure culturally appropriate follow-up arrangements

---

SAQ Practice Questions

SAQ 1: Thoracentesis Technique and Light's Criteria (20 marks)

Stem: A 68-year-old man presents with progressive dyspnea over 2 weeks. He has a history of heart failure (EF 35%) and was recently treated for community-acquired pneumonia. Chest X-ray shows a moderate right pleural effusion. You plan to perform a diagnostic thoracentesis.

Questions:

(a) Describe your technique for ultrasound-guided diagnostic thoracentesis, including patient positioning, site selection, and the Z-track method. (8 marks)

Model Answer:

Patient positioning (2 marks):

• Sitting upright at edge of bed, leaning forward over bedside table
• Arms resting on pillow, shoulders forward to separate ribs
• Alternative: Lateral decubitus with affected side down if unable to sit

Ultrasound assessment (2 marks):

• Curvilinear probe, posterior axillary or midscapular line
• Identify: Pleural effusion (anechoic), diaphragm (hyperechoic), liver/spleen below
• Measure: Fluid depth (>10mm required), distance to diaphragm
• Assess: Loculations, septations, fluid characteristics
• Mark optimal entry point (or use real-time guidance)

Site selection (1.5 marks):

• Posterior axillary line or midscapular line, 7th-9th intercostal space
• Choose intercostal space with maximum fluid depth on USS
• Insert at SUPERIOR border of lower rib (avoid neurovascular bundle)

Z-track technique (1.5 marks):

• Use non-dominant hand to retract skin 2cm caudally (inferiorly)
• Maintain traction throughout needle insertion and aspiration
• Purpose: Creates oblique track through tissues that seals on needle withdrawal
• Prevents: Post-procedure pleural fluid leak, reduces pneumothorax risk

Procedure (1 mark):

• Sterile preparation (chlorhexidine, full draping)
• Local anesthesia (lidocaine 1-2%, anesthetize track including periosteum and pleura)
• Insert needle with constant aspiration until fluid aspirated
• Collect 50-100mL for analysis

---

(b) The pleural fluid results are: Protein 38 g/L, LDH 420 IU/L, pH 7.38, glucose 5.2 mmol/L. Serum protein is 62 g/L, serum LDH is 180 IU/L. Apply Light's criteria and classify this effusion. (6 marks)

Model Answer:

Calculate Light's Criteria (3 marks):

1. Pleural protein: 38 g/L (>30 g/L = exudate criterion)
2. Pleural/Serum protein ratio: 38/62 = 0.61 (>0.5 = exudate criterion)
3. Pleural/Serum LDH ratio: 420/180 = 2.33 (>0.6 = exudate criterion)
4. Pleural LDH: 420 IU/L (if ULN is 200, then >2/3 × 200 = >133 = exudate criterion)

Classification (1 mark):

• ALL FOUR criteria positive for exudate
• This is an exudative effusion

Clinical interpretation (2 marks):

• However, patient has heart failure AND recent pneumonia
• Diuretic therapy can concentrate transudate → "pseudo-exudate"
• Calculate Serum-Effusion Albumin Gradient: Need albumin values
• If gradient >12 g/L, suggests transudate despite Light's criteria
• Clinical context: Could be resolving heart failure effusion concentrated by diuretics, OR parapneumonic effusion
• The normal pH (7.38) and normal glucose (5.2) argue against complicated parapneumonic effusion

---

(c) What are the indications for chest tube drainage rather than simple thoracentesis in parapneumonic effusion? (6 marks)

Model Answer:

Absolute indications for chest tube (3 marks):

1. Frank pus on aspiration (empyema by definition)
2. Positive Gram stain or culture (organisms in pleural space)
3. Pleural fluid pH under 7.2 (complicated effusion)
4. Pleural fluid glucose under 3.4 mmol/L (60 mg/dL) (complicated effusion)
5. Pleural fluid LDH >1000 IU/L (marked inflammation)

Relative indications/considerations (2 marks):

• Loculated effusion on USS (won't drain with simple tap)
• Large effusion occupying >50% hemithorax
• Failure to respond to antibiotics alone
• Clinical deterioration despite appropriate therapy

Management approach (1 mark):

• Simple parapneumonic: Antibiotics alone, serial imaging
• Borderline (pH 7.2-7.3): Close monitoring, low threshold for drain
• Complicated (meets criteria above): Chest tube + antibiotics
• Loculated/complex empyema: Chest tube + intrapleural fibrinolytics (tPA + DNase, MIST-2 protocol)
• Failure of medical management: VATS decortication

---

SAQ 2: Re-Expansion Pulmonary Edema and Complications (20 marks)

Stem: A 45-year-old woman with newly diagnosed ovarian cancer has a large left pleural effusion causing significant dyspnea. She is scheduled for therapeutic thoracentesis. After draining 1.8L of straw-colored fluid, she develops persistent cough and increasing shortness of breath.

Questions:

(a) What is the most likely diagnosis, and what is the underlying pathophysiology? (6 marks)

Model Answer:

Diagnosis (1 mark):

• Re-expansion pulmonary edema (REPE)

Pathophysiology (5 marks):

Chronic lung collapse effects (2 marks):

• Prolonged atelectasis (days to weeks) causes surfactant depletion
• Ischemic injury to pulmonary capillaries during collapse
• Increased pulmonary vascular permeability
• Impaired lymphatic drainage from compressed lung

Reperfusion injury mechanism (2 marks):

• Rapid lung re-expansion causes sudden reperfusion of collapsed lung tissue
• Ischemia-reperfusion injury generates reactive oxygen species (ROS)
• Neutrophil activation and inflammatory mediator release (IL-8, TNF-α)
• Increased capillary permeability → protein-rich fluid leaks into alveoli
• Similar mechanism to reperfusion injury in other organs (MI, stroke)

Clinical result (1 mark):

• Unilateral pulmonary edema (ipsilateral to drained effusion)
• Occasionally bilateral if severe inflammatory response
• Onset during or within 24 hours of drainage

---

(b) What are the risk factors for this complication, and how could it have been prevented? (6 marks)

Model Answer:

Risk factors (3 marks):

1. Large volume drainage: >1.5L in single session (this patient had 1.8L)
2. Chronic lung collapse: Effusion present for >7 days (increased surfactant depletion)
3. Rapid drainage: High-pressure suction rather than slow gravity drainage
4. Large total effusion: Complete drainage of massive effusion
5. Young age: 20-40 years (less compliant lung tissue - though this patient is 45)
6. Extent of collapse: Near-complete lung collapse pre-procedure

Prevention strategies (3 marks):

Volume limitation (1 mark):

• Limit to 1.0-1.5L per session (traditional recommendation)
• Repeat drainage in 24-48 hours if needed

Symptom-guided drainage (1 mark):

• Stop IMMEDIATELY if persistent cough develops (earliest sign)
• Stop if chest tightness, dyspnea develop
• "The patient tells you when to stop" (PMID: 17400840)

Pleural manometry (1 mark):

• Monitor pleural pressure during drainage
• Stop if pleural pressure falls below -20 cmH2O
• Indicates "trapped lung" or excessive negative pressure

Technique (0.5 marks):

• Use slow gravity drainage (not suction)
• Intermittent rather than continuous drainage

---

(c) Outline your management of this patient. (8 marks)

Model Answer:

Immediate actions (2 marks):

1. Stop the drainage - if still ongoing
2. Administer supplemental oxygen - target SpO2 >94%
3. Continuous monitoring - SpO2, HR, BP, respiratory rate
4. Sit patient upright - optimize respiratory mechanics
5. Obtain urgent CXR - confirm REPE, exclude pneumothorax

Assessment (2 marks):

1. Clinical severity assessment:
   • Respiratory rate, work of breathing
   • SpO2 on room air and with supplemental O2
   • Ability to speak in sentences
   • Level of consciousness
2. Exclude other diagnoses:
   • Pneumothorax (can co-exist)
   • Pulmonary embolism
   • Cardiac event (arrhythmia, ACS)

Supportive care (2 marks):

1. Oxygen therapy: Start with facemask, escalate to NIV if needed
2. NIV (if hypoxic despite supplemental O2):
   • CPAP 5-10 cmH2O, or BiPAP 10/5
   • Reduces work of breathing, improves oxygenation
   • May prevent intubation
3. Fluid management: Judicious (not overloading)
4. Diuretics: Limited evidence, consider furosemide if volume overloaded
5. Analgesia: If chest pain present

Escalation (1 mark):

• If severe hypoxia (SpO2 under 88% on high-flow O2) or respiratory failure
• Consider intubation and mechanical ventilation
• Lung-protective ventilation (ARDS protocol)
• ICU admission for monitoring and support

Prognosis and follow-up (1 mark):

• REPE usually resolves in 24-72 hours with supportive care
• Serial CXR to monitor resolution
• Once resolved, can repeat therapeutic thoracentesis with smaller volumes
• Consider indwelling pleural catheter (IPC) for recurrent malignant effusion

---

Viva Scenarios

Viva 1: Thoracentesis Technique and Ultrasound

Examiner: You are the ICU registrar. A 72-year-old man with pneumonia has a moderate right pleural effusion. The admitting team asks you to perform a diagnostic thoracentesis. Talk me through your approach.

Candidate: Thank you. I would approach this systematically, starting with indication, consent, preparation, ultrasound assessment, and then the procedure itself.

Examiner: What is your indication for the procedure?

Candidate: The indication is diagnostic thoracentesis for a parapneumonic effusion. Any patient with pneumonia and a pleural effusion requires sampling to differentiate simple parapneumonic effusion (managed with antibiotics alone) from complicated parapneumonic effusion or empyema (requiring chest tube drainage).

Examiner: What if the patient is on therapeutic anticoagulation?

Candidate: Anticoagulation is NOT an absolute contraindication to thoracentesis when performed with ultrasound guidance. Studies have shown bleeding complications are rare even with therapeutic anticoagulation. I would proceed with the procedure using meticulous ultrasound guidance, though I would consider holding the anticoagulant prior to the procedure if clinically appropriate and discuss with the treating team.

Examiner: Describe your ultrasound assessment.

Candidate: I would use a curvilinear probe, positioning the patient sitting upright and leaning forward. Starting at the posterior axillary line around the 7th-9th intercostal space, I would identify:

1. The ribs - as hyperechoic curved lines with posterior shadowing
2. The pleural effusion - as an anechoic or hypoechoic collection
3. The diaphragm - as a hyperechoic curved line moving with respiration
4. The liver below the diaphragm

I would measure the depth of the fluid pocket (need >10mm for safe tap), note any loculations or septations, and identify my insertion site with adequate distance from the diaphragm.

Examiner: How do you avoid the intercostal vessels?

Candidate: The intercostal neurovascular bundle runs along the inferior border of each rib in the costal groove. The order from superior to inferior is Vein-Artery-Nerve. To avoid these structures, I insert the needle at the SUPERIOR border of the LOWER rib - essentially going just above the rib below my target intercostal space. I can also use color Doppler on ultrasound to visualize the intercostal vessels, which is particularly useful in elderly patients where vessels may be more tortuous.

Examiner: Explain the Z-track technique.

Candidate: The Z-track technique involves retracting the skin approximately 2cm caudally (inferiorly) with my non-dominant hand before inserting the needle. I maintain this traction throughout the procedure. When I remove the needle and release the skin, it returns to its original position, creating a "Z-shaped" or oblique tract through the tissues. This serves two purposes: it helps seal the puncture site to prevent post-procedure air entry (reducing pneumothorax risk) and prevents persistent pleural fluid leak through the tract.

Examiner: What samples do you send?

Candidate: I would collect 50-100mL and send:

1. Biochemistry: Protein, LDH, glucose, pH (in a blood gas syringe, on ice)
2. Microbiology: Gram stain, bacterial culture (aerobic and anaerobic), consider TB culture if indicated
3. Cytology: For cell count and differential, and malignant cells
4. Blood tests: Simultaneous serum protein, LDH, and albumin to calculate Light's criteria and serum-effusion albumin gradient

Examiner: The pH comes back as 7.1. What does this mean?

Candidate: A pH of 7.1 is below the critical threshold of 7.2, indicating a complicated parapneumonic effusion that will NOT resolve with antibiotics alone. This patient requires chest tube drainage. Other markers supporting this would be glucose under 3.4 mmol/L and LDH >1000 IU/L. I would insert a small-bore intercostal drain (12-14 French), continue IV antibiotics, and monitor drainage. If the effusion is loculated and not draining adequately, I would consider intrapleural fibrinolytics (tPA 10mg + DNase 5mg twice daily) based on the MIST-2 trial evidence.

Examiner: What if the fluid is frankly purulent?

Candidate: Frank pus defines empyema, regardless of the pH or biochemistry results. This is an absolute indication for chest tube drainage. I would insert the drain, send the pus for culture (often positive), and continue broad-spectrum antibiotics covering anaerobes (such as piperacillin-tazobactam or meropenem). If drainage is inadequate despite the chest tube, I would add intrapleural fibrinolytics. Surgical referral for VATS decortication may be needed if medical management fails.

---

Viva 2: Light's Criteria and Complications

Examiner: A 58-year-old woman with heart failure has had a thoracentesis. The results show: pleural protein 32 g/L, serum protein 58 g/L, pleural LDH 180 IU/L, serum LDH 150 IU/L. Calculate Light's criteria.

Candidate: I'll calculate each criterion:

1. Pleural protein: 32 g/L - this is just above 30 g/L (borderline exudate criterion)
2. Protein ratio: 32/58 = 0.55 - this is >0.5 (exudate criterion met)
3. LDH ratio: 180/150 = 1.2 - this is >0.6 (exudate criterion met)
4. Pleural LDH: 180 IU/L - if upper limit of normal is 200, then 2/3 is 133, so this is >133 (exudate criterion met)

By Light's criteria, this meets multiple exudate criteria, so technically it would be classified as an exudate.

Examiner: But you said she has heart failure. How do you reconcile this?

Candidate: This is the classic scenario of a "pseudo-exudate." Heart failure causes transudative effusions, but diuretic therapy concentrates the pleural fluid, increasing protein and LDH levels. This can misclassify up to 25-30% of transudates as exudates by Light's criteria.

To differentiate, I would calculate the Serum-Effusion Albumin Gradient:

• Serum albumin - Pleural albumin
• If the gradient is >12 g/L, it suggests a transudate despite meeting Light's criteria

In this clinical context with known heart failure responding to diuretics, I would treat this as a transudative effusion from heart failure, continuing diuretic therapy rather than investigating further for an exudative cause.

Examiner: The patient had 2L drained and now has cough and dyspnea. What's your concern?

Candidate: My primary concern is re-expansion pulmonary edema (REPE). This is a reperfusion injury that occurs when a chronically collapsed lung is rapidly re-expanded. The volume drained (2L) exceeds the recommended maximum of 1.5L per session, increasing the risk.

Other differential diagnoses to consider:

• Pneumothorax (from lung puncture)
• Vasovagal reaction (though this would more likely cause hypotension/bradycardia)
• Pulmonary embolism (coincidental)

Examiner: How would you differentiate REPE from pneumothorax?

Candidate: Clinical features:

• REPE: Usually onset during or shortly after procedure, persistent cough (often the first sign), progressive dyspnea, frothy sputum in severe cases
• Pneumothorax: Sudden chest pain, acute dyspnea, reduced breath sounds on affected side

Examination:

• REPE: Crackles on auscultation of the affected lung
• Pneumothorax: Reduced breath sounds, hyperresonance

Investigations:

• Urgent CXR would differentiate: REPE shows unilateral pulmonary edema (ipsilateral to drainage), while pneumothorax shows visible pleural line with absent lung markings

Management differences:

• REPE: Supportive care, oxygen, potentially NIV, usually resolves in 24-72 hours
• Pneumothorax: May require chest tube insertion if large or symptomatic

Examiner: How do you prevent REPE?

Candidate: Several strategies can prevent REPE:

1. Volume limitation: Limit drainage to 1.0-1.5L per session
2. Symptom monitoring: Stop IMMEDIATELY if persistent cough, chest tightness, or dyspnea develop - "the patient tells you when to stop"
3. Slow drainage: Use gravity rather than active suction
4. Pleural manometry: If available, monitor pleural pressure and stop if it falls below -20 cmH2O
5. Staged drainage: For very large effusions, drain over multiple sessions 24-48 hours apart

Examiner: What is the MIST-2 trial?

Candidate: MIST-2 was a randomized controlled trial published in 2011 (PMID: 21830966) investigating intrapleural therapy for pleural infection.

Design: 210 patients with pleural infection randomized to four groups:

1. tPA + DNase
2. tPA alone
3. DNase alone
4. Placebo

Key findings:

• Only the combination of tPA + DNase was effective
• Improved pleural fluid drainage
• Reduced need for surgical intervention
• Shorter hospital stay
• tPA alone or DNase alone showed no benefit (DNase alone may have been harmful)

Clinical application: For complicated parapneumonic effusions or empyema not draining adequately through a chest tube, we use tPA 10mg + DNase 5mg twice daily instilled through the chest tube. This breaks down fibrin bands (tPA) and reduces the viscosity of pus (DNase), facilitating drainage.